Recent PTAB Decision Highlights Importance of Secondary Considerations in Obviousness Challenges

Jun 2, 2017

Reading Time : 1 min

By: Rubén H. Muñoz, Lance Han, law clerk (not admitted to practice)

The patent at issue in Varian Medical Systems is U.S. Pat. No. 7,471,765 B2 (the “’765 patent”), which generally relates to using a cone-beam CT scanner with a flat-panel imager in conjunction with a radiation therapy system as an image-guided radiotherapy system for increased precision and effectiveness of radiation treatments. The petitioners argued, and the PTAB agreed, that all claim limitations were taught by the combination of prior art references. However, the PTAB also assessed “secondary considerations” in its obviousness inquiry. In doing so, the PTAB found “(1) very strong evidence of industry praise; (2) very strong evidence of long-felt need; (3) moderately strong evidence of commercial success; and (4) moderately strong evidence of copying,” pointing to the nonobvious nature of the ’765 patent and its claims. First, for industry praise, the PTAB found evidence of textbook publications praising the invention, journal publications (“more than 1,000 . . . scientific articles”) citing the invention, and an R&D award from a magazine in 2006. Second, for long-felt need, the PTAB analyzed evidence such as the patent owner’s declaration and deposition testimony, and a journal publication that supported the patent owner’s assertion that the problem the patent purported to solve “need[ed] to be solved, and that it was long-felt at least since ‘the early 1990s.’”  Third, for commercial success, the PTAB found evidence that the majority of sales both worldwide and in North America were made with the claimed invention. Lastly, for copying, the PTAB found evidence that a third party created a product that met all claim limitations.

As a result, despite finding that the prior art, and the combinations of those prior art references, were “well known to one of ordinary skill in the art,” the PTAB ruled that the patent owner’s evidence of secondary considerations, which strongly pointed to nonobviousness, outweighed those findings and thus rejected the petitioner’s obviousness challenge.

Varian Medical Systems, Inc. v. William Beaumont Hospital, IPR2016-00162, Paper 69 (May 4, 2017).

Share This Insight

Previous Entries

IP Newsflash

December 18, 2025

The Federal Circuit recently vacated a $20 million jury verdict in favor of a patentee and remanded with instructions to dismiss the case for lack of subject matter jurisdiction, finding that the patentee did not own the asserted patents at the time it filed suit and therefore lacked standing.

...

Read More

IP Newsflash

December 17, 2025

The Federal Circuit recently affirmed a Patent Trial and Appeal Board decision finding claims that had been subject to an ex parte reexamination unpatentable. As a threshold issue, the court held that IPR estoppel under 35 USC § 315(e)(1) does not apply to ongoing ex parte reexaminations. Accordingly, the Patent Office did not err in continuing the reexamination after issuing final written decisions in co-pending IPRs.

...

Read More

IP Newsflash

December 15, 2025

The District of Delaware recently denied a defendant’s motion to dismiss plaintiff’s demand for enhanced damages based on willful infringement pursuant to 35 U.S.C. § 284, explaining that neither a demand for damages under § 284 nor an accusation of willful infringement amount to a claim for relief that can be subject to dismissal under Rule 12(b)(6).

...

Read More

IP Newsflash

December 9, 2025

The Federal Circuit recently denied a petition for a writ of mandamus that challenged the PTO Director’s reliance on “settled expectations” to discretionarily deny two inter partes review (IPR) petitions. In so doing, the court explained that, while it was not deciding whether the Director’s use of “settled expectations” was correct, the petitioner’s arguments about what factors the Director may consider when deciding whether to institute an IPR or post-grant review (PGR) are not generally reviewable and did not provide sufficient basis for mandamus review here.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.